A Phase 3 interventional study of Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium (BDP/FF/GB) in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 8 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Beclomethasone · Pulmonary Disease, Chronic Obstructive.
Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 13th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 24 across the 13 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 7 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A.: 5 open now, 5 under way, none of them phase 3. Of 62 finished, 7 (11%) have results posted.
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 50th largest by enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2021, is one of 16 in phase 3, and was the 55th registered.
Chiesi Farmaceutici S.p.A.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 68 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical study was to evaluate the tolerability, safety, and efficacy of stepping up from fluticasone propionate (FP)/salmeterol (SLM) dry-powder inhaler (DPI) (SERETIDE™ DISKUS™) to extrafine beclometasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) DPI (CHF5993) and to assess its effect on airway geometry and lung ventilation in subjects with advanced Chronic Obstructive Pulmonary Disease (COPD).
Primary Objectives:
Secondary Objectives:
The study was an open-label, single-arm, prospective study of a duration of approximately 14 weeks per patient, aimed at evaluating the effect of step-up from non-extra fine ICS/LABA DPI to extra fine triple therapy with CHF5993 DPI on airway geometry and lung ventilation using Functional Respiratory Imaging (FRI) in subjects with advanced COPD.
All parameters assessed in this trial were evaluated at the following visits:
The screening visit (V1) was followed by a 6-week run-in phase where participants were stabilized on SERETIDE™ DISKUS™ DPI 500/50μg, one inhalation twice daily (b.i.d.). This regimen provided a total daily dose of 1 mg of fluticasone propionate (FP) and 100 µg of salmeterol (SLM). At the screening visit (V1), patients received specific training on the proper use of the inhalation technique using In-Check Dial for both SERETIDE™ DISKUS™ and CHF5993 NEXThaler®. More precisely, to familiarize participants with the technique and ensure repeatable inhalations one assessment was set up for DISKUS™ resistance and the other for NEXThaler® resistance.
At the end of the run-in period (V2), patients transitioned to a 6-week treatment phase with CHF5993 DPI (until V3).
A follow-up call was conducted 2 weeks ± 2 days after V3 for males and women of non-childbearing potential, FRI, spirometry, and plethysmography were used to evaluate airway geometry, lung ventilation, and lung function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of (WOCBP) fulfilling one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients (25 subjects) received CHF5993 as follows: \- Treatment period (6 weeks): two inhalations b.i.d. of CHF5993 DPI 100/6/12.5 µg, giving a total daily dose of beclometasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) 400/24/50 µg. After the screening visit (V1) that was to be performed 6 weeks ± 2 days before Visit 2 (V2), eligible patients were to undergo a 6-week run-in period with fluticasone dipropionate (FP)/salmeterol (SLM) DPI 500/50 µg (SERETIDE™ DISKUS™). At the end of the run-in period (V2), patients were to be switched to the treatment period with BDP/FF/GB DPI (CHF5993), as said for 6 weeks, until Visit 3 (V3).
Drug: Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium (BDP/FF/GB)
Drug pages: Beclomethasone · Formoterol · Glycopyrrolate
Treatment period: two inhalations b.i.d. of CHF5993 DPI 100/6/12.5 µg, for a total daily dose of BDP/FF/GB 400/24/50 µg. All the eligible patients were treated
Also known as: CHF5993
Untrimmed Airway Volume (siVaw) for Distal Region at Total Lung Capacity (TLC) - Actual Value for V2 Pre-dose and V3 Pre-dose
siVaw was measured using Functional Respiratory Imaging (FRI) at Total Lung Capacity (TLC). siVaw represents the 3D reconstruction and quantification of the volume of air within the segmented airway tree. Higher siVaw values indicate a reduction in airway obstruction and improved ventilation efficiency in the lungs. For patients with COPD, siVaw is typically reduced due to airway obstruction and structural changes in the lungs. The siVaw comparisons were made on 'untrimmed' airways SO that all visible generations in a given scan (from Visit 2 or 3 respectively) were used in order to capture all available volume information. The data were summarized by the descriptive statistics for actual values at each timepoint.
Time frame: V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days)
Trimmed Airway Volume (siRaw) for Distal Region at Total Lung Capacity (TLC) - Actual Value for V2 Pre-dose and V3 Pre-dose
siRaw was measured using Functional Respiratory Imaging (FRI) at TLC. siRaw represents the 3D reconstruction and quantification of resistance to airflow within the segmented airway tree. Lower siRaw values indicate improved airway patency, reduced airflow resistance, and enhanced ventilation efficiency in the lungs. For patients with COPD, siRaw is elevated due to airway narrowing, obstruction, and other structural changes in the lungs. The siRaw was evaluated using 'trimmed' data, meaning that only airway generations visible in both scans (i.e., the same airways) were used. The use of trimmed data in Multidetector computed tomography (MDCT) ensures that differences between scans are solely due to changes in airway calibre, not variations in the number of airway generations included in Computational Fluid Dynamics (CFD) calculations. The data were summarized by the descriptive statistics for actual values at each timepoint.
Time frame: V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days)
Untrimmed Airway Volume (siVaw) for Distal Region at Total Lung Capacity (TLC) - Actual Value for V2 Pre-dose, V2 Post-dose, V3 Pre-dose and V3 Post-dose
Airway volume (siVaw) was measured using Functional Respiratory Imaging (FRI) at TLC. siVaw quantifies the volume of air in the segmented airway tree. Higher siVaw values indicate reduced airway obstruction and improved ventilation. For this outcome, siVaw was assessed in distal lung regions, using 'untrimmed' data to include all visible airway generations. The data were summarized by the descriptive statistics for actual values at each timepoint.
Time frame: V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V2 within 60-120 min post-dose (assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days) and V3 within 60-120 min post-dose (assessed at week 12 ± 2 days)
Untrimmed siVaw for Distal Region at Functional Residual Capacity (FRC) - Actual Value for V2 Pre-dose, V2 Post-dose, V3 Pre-dose and V3 Post-dose
Airway volume (siVaw) was measured using Functional Respiratory Imaging (FRI) at FRC. siVaw quantifies the air volume in the segmented airway tree at the end of a normal exhalation, expressed in milliliters (mL). Higher siVaw values at FRC indicate reduced airway obstruction and improved residual ventilation. In this outcome, siVaw was assessed in central and distal lung regions using 'untrimmed' data, ensuring all visible airway generations were included. Percent change in siVaw was calculated to evaluate treatment effects at these time points: Baseline (V2 pre-dose) to post-dose at V3, reflecting long-term improvements. Pre-dose to post-dose at V2, assessing the acute effect of SERETIDE™ DISKUS™ DPI. Pre-dose to post-dose at V3, assessing the acute effect of CHF5993 DPI. Percentage change from time point t at time point t1 was defined as follows: 100\*((value at time point t - value at time point t1) / value at time point t1)
Time frame: V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V2 within 60-120 min post-dose (assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days), V3 within 60-120 min post-dose (assessed at week 12 ± 2 days)
Trimmed siRaw Via Functional Respiratory Imaging (FRI) for Distal Region at Total Lung Capacity (TLC) - Actual Values for V2 Pre-dose, V2 Post-dose, V3 Pre-dose and V3 Post-dose
Airway resistance (siRaw) was measured using FRI at TLC. siRaw quantifies airflow resistance within the segmented airway tree during inspiration. Lower siRaw values indicate reduced airway resistance, improved airway patency, and enhanced ventilation. For this outcome, siRaw was assessed in central and distal lung regions using 'untrimmed' data, ensuring all visible airway generations were included. The data were summarized by the descriptive statistics for actual values at each timepoint.
Time frame: V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V2 within 60-120 min post-dose (assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days), V3 within 60-120 min post-dose (assessed at week 12 ± 2 days)
Trimmed siRaw for Distal Region Using Functional Respiratory Imaging (FRI) at Functional Residual Capacity (FRC) - Actual Values for V2 Pre-dose, V2 Post-dose, V3 Pre-dose and V3 Post-dose
Airway resistance (siRaw) was measured using Functional Respiratory Imaging (FRI) at Functional Residual Capacity (FRC). siRaw quantifies airflow resistance within the segmented airway tree at the end of a normal exhalation, expressed in cmH₂O·s. Lower siRaw values at FRC indicate reduced airway obstruction and improved airflow efficiency. For this outcome, siRaw was assessed in central and distal lung regions using 'untrimmed' data to include all visible airway generations. The data were summarized by the descriptive statistics for actual values at each timepoint.
Time frame: V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V2 within 60-120 min post-dose (assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days), V3 within 60-120 min post-dose (assessed at week 12 ± 2 days)
In total, 45 patients were screened of whom 20 were screening failures. The other 25 patients were enrolled and received two inhalations b.i.d. of CHF5993 DPI 100/6/12.5 µg. All enrolled and treated patients completed the study, and 23 patients were included in the PP analysis set due to eligibility criteria violations.
| Milestone | CHF5993 DPI 100/6/12.5 μg |
|---|---|
| Started | 25 |
| Saf population | 25 |
| Pp population | 23 |
| Completed | 25 |
| Not completed | 0 |
siVaw was measured using Functional Respiratory Imaging (FRI) at Total Lung Capacity (TLC). siVaw represents the 3D reconstruction and quantification of the volume of air within the segmented airway tree. Higher siVaw values indicate a reduction in airway obstruction and improved ventilation efficiency in the lungs. For patients with COPD, siVaw is typically reduced due to airway obstruction and structural changes in the lungs. The siVaw comparisons were made on 'untrimmed' airways SO that all visible generations in a given scan (from Visit 2 or 3 respectively) were used in order to capture all available volume information. The data were summarized by the descriptive statistics for actual values at each timepoint.
| liters | CHF5993 DPI 100/6/12.5 μg - PP Population |
|---|---|
| Baseline / V2 pre-dose, TLC | 1.4088 ± 0.6647 |
| V3 pre-dose, TLC | 1.3550 ± 0.6014 |
siRaw was measured using Functional Respiratory Imaging (FRI) at TLC. siRaw represents the 3D reconstruction and quantification of resistance to airflow within the segmented airway tree. Lower siRaw values indicate improved airway patency, reduced airflow resistance, and enhanced ventilation efficiency in the lungs. For patients with COPD, siRaw is elevated due to airway narrowing, obstruction, and other structural changes in the lungs. The siRaw was evaluated using 'trimmed' data, meaning that only airway generations visible in both scans (i.e., the same airways) were used. The use of trimmed data in Multidetector computed tomography (MDCT) ensures that differences between scans are solely due to changes in airway calibre, not variations in the number of airway generations included in Computational Fluid Dynamics (CFD) calculations. The data were summarized by the descriptive statistics for actual values at each timepoint.
| cmH₂O·s | CHF5993 DPI 100/6/12.5 μg - PP Population |
|---|---|
| Baseline / V2 pre-dose, TLC | 0.7160 ± 0.4034 |
| V3 pre-dose, TLC | 0.8492 ± 0.5947 |
Airway volume (siVaw) was measured using Functional Respiratory Imaging (FRI) at TLC. siVaw quantifies the volume of air in the segmented airway tree. Higher siVaw values indicate reduced airway obstruction and improved ventilation. For this outcome, siVaw was assessed in distal lung regions, using 'untrimmed' data to include all visible airway generations. The data were summarized by the descriptive statistics for actual values at each timepoint.
| liters | CHF5993 DPI 100/6/12.5 μg - PP Population |
|---|---|
| Baseline / V2 pre-dose, TLC | 1.4088 ± 0.6647 |
| V2 post-dose, TLC | 1.8706 ± 0.4954 |
| V3 pre-dose, TLC | 1.3550 ± 0.6014 |
| V3 post-dose, TLC | 1.9805 ± 0.6390 |
Airway volume (siVaw) was measured using Functional Respiratory Imaging (FRI) at FRC. siVaw quantifies the air volume in the segmented airway tree at the end of a normal exhalation, expressed in milliliters (mL). Higher siVaw values at FRC indicate reduced airway obstruction and improved residual ventilation. In this outcome, siVaw was assessed in central and distal lung regions using 'untrimmed' data, ensuring all visible airway generations were included. Percent change in siVaw was calculated to evaluate treatment effects at these time points: Baseline (V2 pre-dose) to post-dose at V3, reflecting long-term improvements. Pre-dose to post-dose at V2, assessing the acute effect of SERETIDE™ DISKUS™ DPI. Pre-dose to post-dose at V3, assessing the acute effect of CHF5993 DPI. Percentage change from time point t at time point t1 was defined as follows: 100\*((value at time point t - value at time point t1) / value at time point t1)
| percent change of lung volume | CHF5993 DPI 100/6/12.5 μg - PP Population |
|---|---|
| Baseline / V2 pre-dose, FRC | 0.6321 ± 0.3164 |
| V2 post-dose, FRC | 1.0204 ± 0.3404 |
| V3 pre-dose, FRC | 0.6982 ± 0.3198 |
| V3 post-dose, FRC | 1.0442 ± 0.3825 |
Airway resistance (siRaw) was measured using FRI at TLC. siRaw quantifies airflow resistance within the segmented airway tree during inspiration. Lower siRaw values indicate reduced airway resistance, improved airway patency, and enhanced ventilation. For this outcome, siRaw was assessed in central and distal lung regions using 'untrimmed' data, ensuring all visible airway generations were included. The data were summarized by the descriptive statistics for actual values at each timepoint.
| cmH₂O·s | CHF5993 DPI 100/6/12.5 μg - PP Population |
|---|---|
| Baseline / V2 pre-dose, TLC | 0.7160 ± 0.4034 |
| V2 post-dose, TLC | 0.3685 ± 0.1594 |
| V3 pre-dose, TLC | 0.8492 ± 0.5947 |
| V3 post-dose, TLC | 0.3121 ± 0.1416 |
Airway resistance (siRaw) was measured using Functional Respiratory Imaging (FRI) at Functional Residual Capacity (FRC). siRaw quantifies airflow resistance within the segmented airway tree at the end of a normal exhalation, expressed in cmH₂O·s. Lower siRaw values at FRC indicate reduced airway obstruction and improved airflow efficiency. For this outcome, siRaw was assessed in central and distal lung regions using 'untrimmed' data to include all visible airway generations. The data were summarized by the descriptive statistics for actual values at each timepoint.
| cmH₂O·s | CHF5993 DPI 100/6/12.5 μg - PP Population |
|---|---|
| Baseline / V2 pre-dose, FRC | 0.4981 ± 0.3383 |
| V2 post-dose, FRC | 0.2200 ± 0.1664 |
| V3 pre-dose, FRC | 0.3625 ± 0.4733 |
| V3 post-dose, FRC | 0.1889 ± 0.1453 |
Collected over Throughout the study, from screening visit (Week 0, Visit 1), till follow up visit (Week 14 ± 2 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CHF5993 DPI 100/6/12.5 μg - SAF Population | 0/25 (0%) | 0/25 (0%) | 11/25 (44%) |
| Event | CHF5993 DPI 100/6/12.5 μg - SAF Population |
|---|---|
| HeadacheNervous system disorders | 3/25 |
| Pleural calcificationRespiratory, thoracic and mediastinal disorders | 2/25 |
| SciaticaNervous system disorders | 1/25 |
| Hiatus herniaGastrointestinal disorders | 1/25 |
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 1/25 |
| Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 1/25 |
| Hepatic steatosisHepatobiliary disorders | 1/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/25 |
The Safety Analysis Population (SAF) included all 25 patients who received at least one dose of the investigational product (IMP), including SERETIDE™ DISKUS™ DPI in the run-in and CHF5993 DPI in the treatment phase. This population was used to assess safety, including treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). However, only 23 patients were included in the Per Protocol (PP) Population due to eligibility criteria violations.
| Age, Continuous(years) | CHF5993 DPI 100/6/12.5 μg |
|---|---|
| Mean | 65.0 ± 7.7 |
| Sex: Female, Male(Participants) | CHF5993 DPI 100/6/12.5 μg |
|---|---|
| Female | 9 |
| Male | 16 |
| Race (NIH/OMB)(Participants) | CHF5993 DPI 100/6/12.5 μg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 25 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | CHF5993 DPI 100/6/12.5 μg |
|---|---|
| Belgium | 8 |
| Hungary | 17 |
| BMI(kg/m²) | CHF5993 DPI 100/6/12.5 μg |
|---|---|
| Mean | 27.71 ± 5.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.
Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
Data sharing details ↗ · www.chiesi.com
Ran from May 2021 to primary completion in Jan 2022, 7 months.
Results were first posted in Apr 2026, 4 years 3 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 7 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Beclomethasone · Formoterol · Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →